Glycoproteomics-based Liquid-biopsy LDT Development Service for Prostate Cancer
Services Published Data
Glycoproteins of Prostate Cancer
Prostate cancer (PCa) ranks as the second most commonly diagnosed cancer among men. While the serum prostate-specific antigen (PSA) test is utilized for early PCa detection, its accuracy is limited, leading to debates due to the risks of excessive diagnosis and treatment.
Emerging evidence establishes aberrant glycosylation as a dependable hallmark of cancer. The majority of the tumor markers, including PSA, are glycoproteins. Various glycan modifications of PSA, such as sialylation, mainly α2,3-sialylation, core fucosylation, branched N-glycans, and LacdiNAc groups, have been consistently linked to the potential to differentiate between benign prostate conditions and cancer. Additionally, these glycan alterations offer promise in distinguishing various stages of PCa development and aggressiveness. An extensive investigation into glycoproteomics, particularly in the case of PSA, through non-invasive methods becomes essential for a thorough assessment and diagnosis of prostate diseases.
Glycoproteomics-based Liquid-biopsy LDT Development for PCa at Creative Biolabs
Creative Biolabs has pioneered an advanced Glycoproteomics-based Liquid-biopsy LDT Platform, aimed at comprehending the implications of glycosylation alterations in prostate diseases.
-
Analysis of PSA glycosylation
This platform enables comprehensive glycan profiling for individual proteins, such as PSA. Our LDT method selectively enriches PSA from biological samples by immunoaffinity capture. Following enrichment, PSA is reduced and alkylated before digestion with trypsin. Subsequently, the separation of glycopeptides is performed by capillary electrophoresis (CE), which is coupled with MALDI-MS detection, followed by rigorous data processing. This method allows us to uncover changes in the glycan patterns of PSA when compared to healthy controls.
-
Analysis of global glycoproteins
In addition to glycan profiling of a single protein, we offer comprehensive glycoproteomic analysis for global glycoproteins present in samples based on mass spectrometry. Our LDT services include but are not limited to glycopeptide mapping, site occupancy analysis, glycan profiling, intact glycopeptides analysis, and characterization of general glycoproteins.
Advantages
Published data
Prostate cancer (PCa) is one of the most common cancers in men and faces the challenge of insufficient biomarkers for detection and prognosis. Currently, PSA examination has the problem of poor specificity, so new biomarkers are urgently needed. Proteomics, especially glycoproteomics, provides a new way to analyze pathological changes. Glycosylation, a prevalent form of post-translational modification, plays a vital role in biological processes. In the context of prostate cancer, alterations in glycosylation are closely linked to the malignant transformation of tumors. Therefore, glycoproteomic analysis combined with mass spectrometry technology can provide an in-depth understanding of the mechanism of prostate cancer. Currently, the widely used glycoproteomic analysis methods mainly include two strategies: top-down direct protein analysis and bottom-up proteolysis analysis. Although these two methods have potential, they still need to be further optimized in sample preparation and data interpretation for better clinical application.
Fig.2 Bottom-up glycoproteomic analysis method.1
Creative Biolabs provides state-of-the-art liquid biopsy LDT services based on glycoproteomics, offering significant potential for elucidating the impact of glycosylation alterations in prostate diseases. Please feel free to contact us or submit an inquiry directly for more information.
Reference
-
Gabriele, Caterina, et al. "Mass spectrometry-based glycoproteomics and prostate cancer." International Journal of Molecular Sciences 22.10 (2021): 5222. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
Related Services
